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Abstract 
Aim: Acute uveitis and scleritis or episcleritis as categorised by anatomical site of 
inflammation; are most frequently idiopathic or linked to systemic disease. We 
characterised the risk of these conditions in relation to type of diabetes, level of 
glycaemic control, and co-existence of retinopathy. 
Methods: Using the Royal College of General Practitioners Research and 
Surveillance Centre database, we established the prevalence of acute uveitis and 
scleritis  or episcleritis over a six year period among populations without (n=889,856) 
and with diabetes (n=48,584). Among those with diabetes, we evaluated the impact 
of glycaemic control on disease risk. Glycaemic control was stratified using HbA1c 
into good, moderate, poor, and very poor. We utilised regression modelling to 
identify associations, adjusting for known clinical and demographic confounders.  
Results: In people without diabetes 2,528  (0.28%) episodes of acute uveitis and 
1,483 (0.17%) episodes of scleritis or episcleritis were identified compared with 253  
(0.52%) episodes of acute uveitis and 81 (0.17%) scleritis or episcleritis in the 
population with diabetes. Acute uveitis occurred more frequently in patients with 
diabetes; type 1: OR 2.01(95% CI 1.18-3.41; p=0.009), and type 2: OR 1.23 (1.05-
1.44; p=0.01). We established glycaemic control as an important effect modifier for 
uveitis risk in patients with diabetes whereby patients with poorer control suffered 
higher disease burden. These results confirmed a dose-response relationship such 
that very poor glycaemic control (OR 4.72, 95% CI: 2.58-8.65; p<0.001), poor 
glycaemic control  (OR 1.57, 95% CI 1.05-2.33; p=0.03) and moderate control (OR 
1.20, 95% CI 0.86-1.68; p=0.29) were altogether predictive of uveitis. Similar results 
were found for when evaluating the effect of retinopathy staging: proliferative 
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retinopathy: OR 2.42 (1.25-4.69; <p=0.01). No relationship was identified with 
scleritis or episcleritis and diabetes, or glycaemic control. 
Conclusion:  Acute uveitis is more common in patients with diabetes; at highest risk 
are those with type 1 disease and poor glycaemic control. Scleritis or episclertis was 
not related to diabetes or glycaemic control. Glycaemic improvements may prevent 
acute uveitis recurrence. 
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Introduction 
Uveitis, scleritis and diabetes are individual risk factors for blindness. Diabetes is the 
third most common cause of blindness in the western world1, and the most common 
cause of blindness in those of working age 2. Posterior uveitis is the fifth most 
common cause of blindness in industrialised nations3 1. Uveitis involves intraocular 
inflammation and is categorised by its location anatomically, duration and by its 
multifactorial aetiology. It is commonly classified into infectious and non-infectious 
forms, and by the orientation of the inflammation, implicit to the uveal tract of the 
intraocular environment. Anterior uveitis is the most prevalent 4, with idiopathic 
aetiologies being encountered more so than the infectious. Although the vast 
majority of clinical and functional outcomes among this cohort of patient remain 
good, severe forms of disease can have catastrophic implications on a patient’s sight 
3.   
Scleritis involves the inflammation of the sclera and present with a painful red eye 
with or without visual loss, much like uveitis its aetiology is multifactorial, often linked 
to systemic autoimmune disease and is classified by location of inflammation around 
the globe (anterior or posterior) and type of disease (necrotizing/ Non-necrotizing : 
diffuse/nodular). It has been shown to cause vision loss (a permanent drop in 
Snellen acuity of two or more lines) in 9% of patients with diffuse anterior disease, 
26% in patients with nodular scleritis, 74% in those with necrotizing disease and 84% 
in those with posterior scleritis 5. Most cases are managed empirically with the use of 
anti-inflammatory therapy6, with little consideration given to prevention apart from 
posterior forms of scleritis due to its potential for acute sight loss.. 
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Episcleritis, however is a benign self-limiting inflammatory disease that affects the 
episclera commonly managed without complications.  It can cause a diagnostic 
challenge at times to differentiate between the disease and scleritis,;  with initial 
clinical features of the two diseases shown to be very similar 7. Patients present with 
discomfort and localised injection. It is classified into two forms, simple and nodular 
with severe forms of disease requiring topical steroids.  
Poor glycaemic control in diabetes has been associated with an increased risk of 
microvascular, macrovascular and infectious complications 8, 9. It is diabetic 
retinopathy and maculopathy that are responsible for the visual impairment in this 
group. Of an estimated 285 million people with diabetic retinopathy worldwide, one 
third have retinal microvascular complications, and in a third of this population the 
complications threaten vision10.  
Individually, these conditions may have a profound effect on an individual’s capacity 
to see, and when a patient presents with more than one condition together the effect 
can often lead to accelerated 11, irreversible impairment to the patient’s vision and 
can provide a clinical challenge to manage in both primary and secondary care. We 
explored whether acute presentations of uveitis and scleritis or episcleritis were 
associated with diabetes and attempted to investigate if glycaemic control influenced 
risk of occurrence. It has long been suggested that there is a relationship between 
type 1 diabetes and uveitis and a potential association with poor glycaemic control, 
however a recent review 12 found no large scale studies assessing these 
relationships. The authors concluded that the association between diabetes and 
uveitis is contentious and requires further research.12 There is an even great paucity 
of data on any potential relationship with type 2 diabetes,12 and to our knowledge no 
research has established whether diabetes type holds additional prognostic value for 
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 5 
predicting uveitis risk. Given these outstanding questions we feel that the data from 
our large-scale cohort study (despite the limitations of such studies) still provides a 
significant addition to the existing literature 
We hypothesised: 
 The diabetic population would have a higher frequency of acute episodes of 
disease in comparison to the general population 
 People with diabetes and poor glycaemic control would be more prone to risk 
of acute disease in comparison to patients with better glycaemic control  
 
Methods  
Utilising the Royal College of General Practitioners (RCGP) Research and 
Surveillance Centre (RSC) database we performed a retrospective cohort study with 
a nested investigation of glycaemic control and of pre-existing retinopathy in people 
with diabetes.  The RCGP RSC database is made up of UK primary care data, this 
data source lends itself to this type of study because practices have been 
computerised since the late 1990s and there is a registration-based system with one 
patient registered with a single practice.  Care is free at the point of delivery.  
Our retrospective cohort study analysed the frequency of these inflammatory 
diseases in the population with diabetes in comparison to those without diabetes. 
The nested study investigated those with diabetes to evaluate what, if any, 
association existed between glycaemic control and episodes of acute uveitis and 
scleritis.  The nested study incorporated data for stage of retinopathy and 
maculopathy; due to its already well-documented relationship to glycaemic control 13.  
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Data Source 
The characteristics of the RCGP-RSC population and participating practices has 
been described elsewhere 14 15The electronic database contains information on over 
1 million patients assembled from over 100 GP practices across England.  
Information is coded by participating practices for biochemical, prescription, 
diagnostic and demographic data into computerised medical record (CMR) systems 
as part of routine care16. Data within the RCGP RSC database is extracted from 
primary care records. In the UK patients are only able to register with a single GP 
practice. The results of any secondary care encounters, such as contact with an 
ophthalmologist are reported to the patients' GP in written letters and any new 
diagnoses are coded into their primary care record. 
 
Study population and the definition of variables  
A six-year study period was defined between the dates of 1st of January 2010 and 
31st December 2015.  All patients fully registered with an RCGP RSC general 
practice and aged ≥ 15 were included for analysis, we did not include temporary 
residents. We excluded patients from analysis when we could not establish the type 
of diabetes. 
Structured data were extracted to ascertain patient information in relation to the 
demographics, conditions and biochemical data.  Coded disease data were recoded 
by all participating practices using the Read classification17.  Diabetes was identified 
using codes for recoded diagnosis, diabetes clinical review, diabetic medication 
(including oral hypoglycaemic agents, excluding metformin and agents commonly 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
 7 
injected by this cohort) and the use of laboratory results.  We have a well-established 
approach to validating diabetes diagnoses 18, 19 This consisted of two or more HbA1c 
values identified to be consistent with a diagnosis of diabetes and depending on test 
provenance; fasting, random, glucose tolerance test 20.  
 
Other variables that could potentially influence prediction on acute episode were also 
extracted from the coded database. This included patient age, gender, deprivation 
quintile, ethnicity, body mass index (BMI) and presence of connective tissue 
disorder. These were defined as following: 
 Age: At the start of the study period (1st January 2010), only those 15 years 
old and older were included   
 Gender: Male or Female 
  Deprivation Quintile: 1 to  5 as measured using the Index of Multiple 
Deprivation the National official measure defined by Public Health England 
and used by the National office of Statistics 21 
 Ethnicity: Asian, Black, Mixed, White or Other ethnic group (categories as 
defined by the Office for  
National Statistics and Public Health England) 22 
 BMI: categorised as <18·5, 18·5 to 25, 25 to 30, and >30 kgm-2 
 Connective tissue disorder: Underlying diagnosis made prior to, or during 
study period: present or absent 
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Acute ocular disease investigated included uveitis and scleritis or episcleritis.  Due to 
the nature of coding in primary care, scleritis and episcleritis were grouped together 
for the purposes of our analysis. We were unable to differentiate between infective 
and non-infectious causes, and thus all results were included in our study. Codes 
that related to traumatic, or chronic causes were excluded from our study. 
Medications were not used to identify disease, as we felt the medication used to treat 
these diseases were primarily started in secondary care and was not reliable due to 
the broad application of use. 
 
Diabetes and its relationship to acute Uveitis and Scleritis  or episcleritis 
In our retrospective cohort study we compared the occurrence of acute episodes in 
people with diabetes in comparison to those without. Individual episodes of disease 
were categorised as a binary outcome (whether they occurred; yes or no) and as a 
categorical outcome (whether they did not occur, occurred once, twice and so on). 
We utilised logistic regression models when looking at the relationship between 
diabetes and individual disease and ordinal regression in cases involving categorical 
count outcomes. Confounders that were included in our models included: age, 
gender, ethnicity, deprivation quintile, body mass index (BMI), diagnosis of 
connective tissue disorder and type of diabetes (Type 1 or 2). 
 
Glycaemic control and its association to acute Uveitis and Scleritis or 
Episcleritis  
The nested study only involved people with diabetes. We aimed to analyse the 
influence of glycaemic control on acute episodes of uveitis and scleritis or episcleritis 
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 9 
and to investigate if there was any additional influence of the stage of retinopathy. 
We used two different measures of glycaemic control to determine association. We 
used:  (1) The single HbA1c measure found to closest to the start of our study 
period; and (2) Measurements of HbA1c calculated from the areas under the curve, 
over the whole study period, an approach based on that of Maple-Brown et al 23.   
We found that the choice of HbA1c did not significantly impact our findings and 
therefore we report our findings using the area under the curve (Table 2) 
The equation used was:  
 
N= Number of hbA1c measurements in totality during the observation period 
Hn = HbA1c value at time n,  
tn = time between Hn and Hn+1 
 
HbA1c results we initially included as a linear variable in our regression models, 
however we found that the relationship between HbA1c and uveitis was non-linear. 
HbA1c results were subsequently stratified as good (<7% (<53mmol/mol)) moderate 
(7-8.4%(53-68mmol/mol)), poor (8.5-11.3% (69-100mmol/mol)) and very poor 
(>11.3% (>100mmol/mol)). We have previously demonstrated that these strata 
helpfully categorise the association between glycaemic control and infection 
prevalence in a number of systemic infections 24 and more recently ocular infections 
9.  Other variables included within the nested element of the study, included: age, 
gender, ethnicity, BMI, diagnosis of connective tissue disorder, stage and diagnosis 
of retinopathy and diagnosis of maculopathy. 
Retinopathy was categorised as per national screening guidelines:  none, non-
specific, background, pre-proliferative and proliferative.25  Maculopathy was 
categorised as present or absent.  
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Statistical Analysis  
We utilised R Version 3.2.5 for data analysis. Acute episodes were corroborated to 
outcome variables. This was done in both binary and categorical counts for all the 
models created. Individual regression models were created to look at acute uveitis 
and scleritis. In instances where no cases of disease were identified for a specific 
variable category we did not report an Odds Ratio (OR) for that variable category. 
Subsequently adjusted ORs and 95% confidence intervals were reported with their 
associated p-value. Results were deemed significant if they were associated with a 
p-value significance level of <0.05. 
 
Ethical considerations: 
This study was classified by the Medical Research Council (MRC) Health Research 
Authority (HRA) tool as a Service Evaluation and the study was also approved by the 
RCGP study review processes reference: RSC_2617. 
 
 
 
Results  
Patient Characteristics 
939,028 people were available to be included in our study. People were excluded if 
we were unable to define the type of diabetes (n=588) or were aged <15 years. This 
provided us with a final total population of 938,440. Of these patients 48,584 were 
identified to have diabetes: Type 1 (n=3,273) and Type 2 (N=45,311). A full 
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description of our patient characteristics have been published elsewhere, (a brief 
summarised form is noted in Table 1) 26 . During the follow up period we identified a 
total of 4,011 episodes of acute uveitis or scleritis or episcleritis in the entire 
population, which consisted of:  acute Uveitis (n= 2,528) and Scleritis or Episcleritis 
(n= 1,483).  Within the diabetic cohort we identified a total of 334 total episodes of 
disease: Uveitis (n=253) and Scleritis or Episcleritis (n=81). 
 
The association between diabetes, acute uveitis and scleritis or episcleritis 
Utilising logistic regression models we completed an initial analysis on the entire 
population (Table 2). We identified that the risk of an episode of acute uveitis to 
increase with age, with the highest risk seen in those aged between 60 and 75 
years.  Acute uveitis was found to occur more commonly in the Asian and Black 
population with no significant variation noted when patients were stratified by 
socioeconomic deprivation or BMI. Acute uveitis was significantly more common in 
people with type 1 diabetes and type 2 diabetes, than in those without diabetes after 
adjusting for confounders. 
 
Conversely scleritis or episcleritis was found to occur least commonly in patients 
aged between 15-30 or over the age of 75. No variation was identified by ethnicity 
however increased episode risk was found to be associated with socioeconomic 
deprivation quintiles 4 and 5 (the most deprived groups). No such relationship was 
identified between diabetes and scleritis or episcleritis. 
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The association between glycaemic control acute uveitis and scleritis or 
episcleritis 
Within the diabetes cohort we did not find any association with acute uveitis and age, 
sex or socioeconomic deprivation; however we did note increased episode 
occurrence risk in those from Asian and Black ethnic backgrounds (Table 3). We 
identified an increased risk of disease with worsening glycaemic control with the 
greatest risk seen in those with an HbA1c >11.3% (>100 mmol/mol). There was no 
relationship with retinopathy other than an increased risk in those with a diagnosis of 
proliferative disease. Figure 1 displays the odds ratios derived from the multi-variable 
logistic regression, illustrating the magnitude of effect of modifiable risk factors 
included in the model (HbA1c and retinopathy categories). We find HbA1c (> 11.3%) 
and proliferative retinopathy are most predictive of uveitis. We also see HbA1c 
maintains a dose-response relationship for predicting uveitis, whereby the predictive 
risk for uveitis increases according to the severity of glycaemic control (Figure 1).  
Whilst males appeared to have fewer episodes of scleritis or episcleritis, no 
statistically significant relationship was identified with age, ethnicity, glycaemic 
control, retinopathy, and maculopathy or socioeconomic deprivation quintile within 
the diabetic population (Table 2).  
 
Discussion 
Our results found episodes of acute uveitis to occur more frequently in people with 
diabetes, particularly in those with type 1 disease. Prevalence had a linear 
association with worse glycaemic control. No significant relationship was found 
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between scleritis or episcleritis, diabetes, glycaemic control, retinopathy or 
maculopathy.  
Our study is the first large population study to clearly demonstrate the relationship of 
glycaemic control on the prevalence of acute uveitis, whilst simultaneously 
confirming its relationship to microvascular complications frequently seen in those 
with poor control. Although scleritis, episclertis and uveitis can be multifactorial in 
aetiology, our results would suggest different pathological processes that influence 
recurrent episodes of disease, particularly in people with diabetes. Our results 
suggest that glycaemic control could be a major modifiable risk factor in preventing 
the occurrence and recurrence of acute uveitis in people with diabetes. 
 
Limitations and strengths of our study 
 
The primary strengths of our study include the population size and the high quality of 
routine data collection that is provided by the RCGP RSC practice network. We have 
been able to look at several associations over a long period of time. Our population 
size is also larger than any study looking at these associations to date. Limitations 
include those of any retrospective database observational study.  This includes our 
inability to exclude residual confounding; we were unable to demonstrate causal 
relationships. Additionally due to either infrequency of disease on a whole, or poor 
transfer of recording from secondary care to primary care, our population size ideally 
would be increased to better identify associations. Due to data quality limitations and 
numbers, we decided to group together the various forms of each disease that are 
generally separated into anatomical site and aetiology. This hindered are ability to 
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differentiate between scleritis and episcleritis. Primary care coding practices at 
present, commonly code these two clinically varied diseases together. In optimal 
conditions sub categorized forms of uveitis, scleritis and episcleritis should be 
studied 
 Uveitis, we would have liked to classify into anterior, posterior, intermediate, 
panuveitis and scleritis into anterior, posterior, nodular, and necrotizing and 
Episcleritis into its simple and nodular forms.  However these were poorly 
differentiated in primary care data. We would also have liked to investigate the 
diseases aetiologically to see if idiopathic forms of disease varied in comparison to 
infectious or autoimmune associated presentations, but again this data was limited 
and poorly recorded. 
There is also a possibility that a number of patients are incorrectly or not coded onto 
primary care systems leading to missed episodes of disease we are unable to 
identify.  There is also a large population that directly presents to secondary care, 
and whilst these encounters are routinely communicated to the patients GP in 
primary care, information transfer inevitably leads to missed cases and recording 
bias. We were also unable to look at a number of patient important and clinical 
outcomes including visual acuity, intraocular pressure and clinical presentation 
findings which are usually recorded in free text in the record and not available for 
researchers; all of which would be useful in better understanding this relationship.  
Finally it must also be noted that the ratio of scleritis/episcleritis to uveitis cases may 
indeed seem higher than noted in practice by many ophthalmologists. We feel that 
this is likely due to the prism of secondary care referrals with our data being 
collected from a primary care source; this may indeed suggest many simple cases of 
episcleritis being managed in the community. 
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Information on the source of the diagnosis –whether this was made by GP or 
specialist—was not available in our dataset. It is therefore possible that there are 
cases where an incorrect diagnosis has been made. However current UK guidelines 
recommend that all suspected cases of uveitis, scleritis, and episcleritis are referred 
urgently to secondary care for management27 and therefore the majority of 
diagnoses are likely to have been made by an ophthalmologist and coded 
retrospectively into the primary care record.  
When considering the detection of concomitant eye disease, we acknowledge the 
possibility of ascertainment bias in the diabetic population. Diabetic Retinopathy 
guidelines published by the Royal College of Ophthalmologists suggest regular 
review for patients with signs of diabetic retinopathy. These vary between a few 
weeks to months before reassessment. Although this cohort of patients are indeed 
under close monitoring, uveitis is commonly an acute presentation that can be 
exceptionally painful and debilitating. Patients commonly seek urgent medical advice 
within a few days of onset and are immediately referred for ophthalmology review.  
While there may be a greater chance for ophthalmologists to detect conditions with 
insidious onset such as cataracts during routine screening, we would argue acute 
inflammatory presentations of uveitis or scleritis would not be discovered during 
routine ophthalmology assessments. 
 
Comparison with the literature 
There is a significant paucity of information that has been able to truly define the 
relationship between diabetes, uveitis or scleritis. Studies have been largely 
underpowered, have not attempted to define to a relationship or have simply 
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attempted to look at ophthalmic outcomes in an attempt to better understand clinical 
course. 
 
A recent systematic review highlighted this significant lack of information and 
conflicting reports relating to diabetes and intraocular inflammation. It highlighted the 
relationship between uveitis and diabetes and determined the need for more studies 
to conclude if an association truly exits12. This relationship between diabetes and 
anterior uveitis was first described more than 100 years ago 28.  With associations 
suggesting that patients with non-insulin diabetics to be more prone to suffer from 
idiopathic anterior uveitis in comparison to acute disease secondary to underlying 
systemic disease29.  A number of different case resorts have highlighted the link 
between uveitis and diabetes 30 31, 32. With a number of authors even defining 
diabetes related uveitis occurring in the presence of poorly controlled diabetes 
without any other underlying cause of disease. 33, 34. Only one other study has 
attempted to look characteristics of patients with uveitis and diabetic eye disease 
and was published in 201334 . This was disadvantaged by their population size 
(n=36: type 1=1, type 2=35). They were however able to demonstrate a raised mean 
Hba1c of 9.5% (80mmol/mol) in acute phases of disease. They also suggested an 
increased risk of progression of retinopathy stage due to poor glycaemic control for 
patients with recurrent disease.  This dataset was collected from secondary care 
data, and thus was also able to report on visual outcomes and better classify type of 
uveitis. Another study attempting to examine cases of anterior uveitis in patients with 
diabetes (n=28) found that patients without diabetic retinopathy were more likely to 
develop anterior uveitis and this was seen more frequently in patients who were 
being treated with insulin and glybenclamide 35. Authors concluded that progression 
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of disease and diabetes was not related to the presence of anterior uveitis.  Other 
studies have looked to identify optimal treatment protocols for patients that suffer 
from uveitis.  A team part of the ‘visual loss in uveitis’ based at Moorfields hospital in 
England identified 96 patients with chronic uveitis and a diagnosis of diabetes 36. 
They however did not examine the role of glycaemic control on relapse rate. Patients 
with uveitis and diabetes appeared to have a significant reduction in visual acuity 
when followed up over two years36.  
Many have postulated a possible immunological link between diabetes and uveitis 37. 
One must remember that inflammation does indeed play an important role in the 
pathophysiology of both diabetic retinopathy and acute uveitis. 33, 38.  The basis of 
which is attributed to dysfunction of the blood-ocular barrier. This includes the up 
regulation of pro-inflammatory factors such as interleukin-1 Beta, IL-6, IL-8, 
interferon induced protein 10 and tumour necrosis factor alpha in diabetic retinopathy 
and over 16 different vascular endothelial growth factor independent inflammatory 
cytokines which have been implicated in proliferative retinopathy12. The earlier 
mentioned systematic review looking at the relationship between diabetes and 
uveitis identified a total of 82 reported case report or series on patients to have both 
diabetes and uveitis. Only 30 patients had type of diabetes highlighted, of which 
76.7% of patients were type 1 and 23.3% having type 2 diabetes. Results that 
appear to be consistent with our findings with a total prevalence deemed to be 
between 7-13% of an underlying diagnosis of diabetes on first presentation with 
acute uveitis. However, they felt that there were conflicting results with some reports 
relating this high incidence of diabetes attributed to an aging population. 
Nonetheless, we have attempted to better delineate this relationship. 
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Information accurately describing the relationship, and clinical course of diabetic 
patients with scleritis or episcleritis is limited. A very few case reports have 
suggested possible diabetes as an underlying cause of infectious scleritis39. Studies 
attempting to establish the characteristics of those with scleritis have noted up to 
20% patients with an underlying diagnosis of diabetes40. Despite these suggested 
associations, there has been no published epidemiological study that has examined 
the potential correlations between diabetes and anterior uveitis, scleritis/  episclertis, 
or attempted to determine the role of glycaemic control in people with diabetes.  This 
is despite suggestions that those with underlying diabetes have more severe forms 
of disease, leading to potentially catastrophic ocular and systemic outcomes41. 
 
Conclusions 
Poor glycaemic control further in diabetes increases the risk of acute uveitis, with 
patients that have an HbA1c over >11.3% (100mmol/mol) almost 5 times more likely 
to have an event.  Acute uveitis was also more common in those with proliferative 
retinopathy. Scleritis or episcleritis was not found to be associated with diabetes, 
glycaemic control, or retinopathy.  Acute uveitis is more common in patients with 
diabetes; those at highest risk are patients with type 1 disease.   
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Patient Characteristics 
Table 1. The Summarised demography of the 938,440 people included in the study: Including age, 
gender, connective tissue disorder, stage of retinopathy and HbA1c.  
 
 
Demographic Without a diagnosis of 
Diabetes (N=889,856) 
Diagnosis of Diabetes 
(N=48584) 
Age:     
15 - 30 237,507 (26.7%) 1,175 (2.4%) 
30 - 45 242,706 (27.3%) 4,018 (8.3%) 
45 - 60 202,340 (22.7%) 11,307 (23.3%) 
60 - 75 135,580 (15.2%) 18,539 (38.2%) 
75 + 71,723 (8.1%) 13,545 (27.9%) 
   
Gender: Male 432,950 (48.7%) 26,756 (55.1%) 
Female 456,906 (51.3%) 21,828 (44.9%) 
   
Connective Tissue Disorders 8,384 (0.9%) 1,212 (2.5%) 
   
Type of Diabetes:   
1 - 3,273 (6.7%) 
2 - 45,311 (93.3%) 
   
Stage of Diabetic 
Retinopathy:   
None - 13,742 (28.3%) 
Non specific - 19,070 (39.3%) 
Background - 13,088 (26.9%) 
Preproliferative - 1,596 (3.3%) 
Proliferative - 1,088 (2.2%) 
Presence of Maculopathy - 2,949 (6.1%) 
   
HbA1c %(mmol/mol)   
<7%(<53) (ref) - 16,950 (34.9) 
7%-8.4%(53-69) - 15,768 (32.5) 
8.5%-11.3%(69-100) - 7,225 (14.9) 
>11.3%(>100) - 747 (1.5) 
Unknown - 7,894 (16.2) 
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Entire Study population model results 
 
Table 2: Results from regression models looking at diabetes as a variable for Acute uveitis and scleritis or 
episcleritis. Models adjusted for gender, age, ethnicity, deprivation quintile, BMI and diagnosis of connective 
tissue disorder. 
 
 
 
 
 
 
 
 
 
Variables Acute uveitis Scleritis or Episcleritis 
 
Odds Ratio 
(95% CI) 
p value Odds Ratio 
(95% CI) 
p value 
Age: 15-30 0.53 (0.44-0.63) p<0.0001 0.39 (0.32-0.48) p<0.0001 
30-45 (ref) 1 - 1 - 
45-60 1.65 (1.45-1.88) p<0.0001 1.13 (0.97-1.31) p=0.1123 
60-75 1.97 (1.72-2.26) p<0.0001 0.95 (0.80-1.13) p=0.5848 
75+ 1.54 (1.29-1.83) p<0.0001 0.45 (0.34-0.59) p<0.0001 
     
Gender:    Male 1.02 (0.93-1.11) p=0.7456 0.56 (0.50-0.64) p<0.0001 
     
     
Ethnicity:     Asian 1.65 (1.38-1.97) p<0.0001 1.24 (0.97-1.59) p=0.0815 
Black 2.17 (1.79-2.64) p<0.0001 1.18 (0.86-1.62) p=0.3146 
Mixed 1.74 (1.19-2.53) p=0.0040 1.09 (0.62-1.93) p=0.7679 
White (ref) 1 - 1 - 
Other 0.90 (0.54-1.50) p=0.6777 0.73 (0.36-1.47) p=0.3739 
     
BMI     
<18.5 0.83 (0.54-1.26) p=0.3785 0.46 (0.23-0.93) p=0.0302 
18.5≥24.9 (ref) 1 - 1 - 
25≥29.9 1.00 (0.88-1.14) p=0.9993 1.14 (0.96-1.35) p=0.1239 
≥30 1.22 (1.06-1.40) p=0.0046 1.18 (0.99-1.42) p=0.0712 
None 1.03 (0.91-1.17) p=0.6320 1.01 (0.86-1.18) p=0.9504 
     
Deprivation Quintile     
1 (ref) 1 - 1 - 
2 1.08 (0.92-1.27) p=0.3235 0.90 (0.71-1.14) p=0.3731 
3 1.22 (1.04-1.42) p=0.0151 1.31 (1.05-1.62) p=0.0162 
4 1.14 (0.97-1.32) p=0.1058 1.49 (1.21-1.83) p=0.0001 
5 1.20 (1.03-1.39) p=0.0172 1.64 (1.35-1.99) p<0.0001 
     
Connective Tissue 
Disorders 1.94 (1.47-2.56) p<0.0001 3.04 (2.21-4.18) p<0.0001 
     
Diabetes     
No diabetes (ref) 1 - 1 - 
Type1 2.01 (1.18-3.41) p=0.0099 1.08 (0.45-2.60) p=0.8687 
Type2 1.23 (1.05-1.44) p=0.0098 0.84 (0.64-1.10) p=0.2087 
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Diabetic Population Models 
Table 3: Results from regression models looking at glycemic control within the diabetic population, as a 
variable for acute uveitis and scleritis or episcleritis. Models are adjusted for age, gender, ethnicity, body mass 
index (BMI), the presence of connective tissue disorders, the degree of retinopathy, the presence of maculopathy 
and deprivation quintile.  
 
Variables Acute uveitis Scleritis or Episcleritis 
 
Odds Ratio 
(95% CI) 
p value Odds Ratio 
(95% CI) 
p value 
Age:  15-30 1.51 (0.61-3.73) p=0.3673 0.81 (0.09-6.98) p=0.8473 
30-45 (ref) 1 - 1 - 
45-60 1.46 (0.84-2.55) p=0.1774 1.44 (0.54-3.81) p=0.4679 
60-75 1.29 (0.74-2.26) p=0.3681 0.99 (0.38-2.63) p=0.9895 
75+ 1.42 (0.79-2.55) p=0.2463 0.51 (0.17-1.55) p=0.2359 
     
Gender:       Male 0.96 (0.73-1.27) p=0.7879 0.45 (0.27-0.75) p=0.0020 
     
Ethnicity:     Asian 2.09 (1.40-3.11) p=0.0003 1.66 (0.80-3.45) p=0.1729 
Black 2.17 (1.24-3.79) p=0.0063 0.80 (0.19-3.39) p=0.7629 
Mixed 1.91 (0.60-6.06) p=0.2712 3.24 (0.78-13.55) p=0.1071 
White (ref) 1 - 1 - 
Other 2.38 (0.74-7.59) p=0.1440 No cases No cases 
     
Deprivation Quintile     
1 (ref) 1 - 1 - 
2 1.51 (0.94-2.42) p=0.0874 1.23 (0.54-2.80) p=0.6234 
3 1.86 (1.17-2.96) p=0.0084 0.92 (0.38-2.23) p=0.8480 
4 1.54 (0.95-2.48) p=0.0781 0.79 (0.32-1.96) p=0.6164 
5 
1.75 (1.11-2.76) p=0.0157 1.79 (0.85-3.74) p=0.1241 
     
Connective Tissue Disorders 1.04 (0.42-2.54) p=0.9332 4.10 (1.74-9.68) p=0.0013 
     
Retinopathy:     
None (ref) 1 - 1 - 
Background 0.89 (0.57-1.41) p=0.6234 2.03 (0.89-4.65) p=0.0944 
Non-specific 1.18 (0.78-1.78) p=0.4357 1.27 (0.56-2.89) p=0.5744 
Preproliferative 1.68 (0.87-3.24) p=0.1218 1.07 (0.21-5.50) p=0.9314 
Proliferative 2.42 (1.25-4.69) p=0.0089 1.68 (0.33-8.59) p=0.5323 
Maculopathy 1.15 (0.71-1.87) p=0.5661 1.50 (0.63-3.54) p=0.3592 
     
HbA1c %(mmol/mol)     
<7%(<53) (ref) 1 - 1 - 
7%-8.4%(53-69) 1.20 (0.86-1.68) p=0.2932 1.07 (0.61-1.87) p=0.8177 
8.5%-11.3%(69-100) 1.57 (1.05-2.33) p=0.0269 0.89 (0.42-1.89) p=0.7669 
>11.3%(>100) 4.72 (2.58-8.65) p<0.0001 No Cases No Cases 
Unknown 0.31 (0.14-0.67) p=0.0029 0.44 (0.12-1.61) p=0.2139 
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Caption: This visual representation of data reflects findings from the multi-variable logistic regression analysis constructed to establish risk factors for uveitis 
among diabetic populations (Table 3). This graph includes the odds ratios and corresponding 95% confidence intervals presented on a logarithmic scale. 
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